Testosterone use in postmenopausal women

References

• Burger HG, Hailes J, Menelaus M. The management of persistent symptoms with estradiol-testosterone implants: clinical, lipid and hormonal results. Maturitas 1984;6:351
   PubMed Web of Science ®Google Scholar
• Davis SR, McCloud PI, Strauss BJG, et al. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227–36
   PubMed Web of Science ®Google Scholar
• Greenblatt RB. Testosterone proprionate pellet implanation in gyneic disorders. JAMA 1943;121:17–24
   Google Scholar
• Greenblatt RB, Barfield WE, Garner JF, et al. Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J Clin Endocrinol Metab 1950;10:1547–58
   PubMed Web of Science ®Google Scholar
• Davis SR, Wahlin-Jacobsen S. Testosterone in women–the clinical significance. Lancet Diabetes Endocrinol 2015;3:980–92
   PubMed Web of Science ®Google Scholar
• Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019;7:754–66
   PubMed Web of Science ®Google Scholar
• Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric 2019;22:429–34
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152–82
   PubMed Web of Science ®Google Scholar
• Judd HL, Lucas WE, Yen SS. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. Am J Obstet Gynecol 1974;118:793–8
   PubMed Web of Science ®Google Scholar
• Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113–8
   PubMed Web of Science ®Google Scholar
• Labrie F, Luu-The V, Labrie C, et al. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 2001;22:185–212
   PubMed Web of Science ®Google Scholar
• Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967;46:891–902
   PubMed Web of Science ®Google Scholar
• Melmed S, Polonsky KS, Larsen PR, et al. Disorders of the Female Reproductive System. Williams Textbook of Endocrinology 12th edition. Philadelphia, USA: Saunders, Elsevier; 2011. 610–33
   Google Scholar
• Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016;37:467–520
   PubMed Web of Science ®Google Scholar
• Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966;45:301–13
   PubMed Web of Science ®Google Scholar
• Skiba MA, Bell RJ, Islam RM, et al. Androgens during the reproductive years, what's normal for women? J Clin Endocrinol Metab 2019;104:5382–92
   PubMed Web of Science ®Google Scholar
• Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–53
   PubMed Web of Science ®Google Scholar
• Davis SR, Bell RJ, Robinson PJ, et al. Testosterone and estrone increase from the age of 70 years: findings from the Sex Hormones in Older Women Study. J Clin Endocrinol Metab 2019;104:6291–300
   PubMed Web of Science ®Google Scholar
• Cappola AR, Ratcliffe SJ, Bhasin S, et al. Determinants of serum total and free testosterone levels in women over the age of 65 years. J Clin Endocrinol Metab 2007;92:509–16
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396–402
   PubMed Web of Science ®Google Scholar
• Dunn JF, Nisula BC, Rodboard D. Transport of steroid hormones. Binding of 21 endogenous steroids to both testosterone-binding globulin and cortico-steroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981;53:58–68
   PubMed Web of Science ®Google Scholar
• Handelsman DJ. Free testosterone: pumping up the tires or ending the free ride? Endocr Rev 2017;38:297–301
   PubMed Web of Science ®Google Scholar
• Goldman AL, Bhasin S, Wu FCW, et al. A Reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev 2017;38:302–24
   PubMed Web of Science ®Google Scholar
• Clayton AH, Goldstein I, Kim NN, et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc 2018;93:467–87
   PubMed Web of Science ®Google Scholar
• Zheng J, Skiba MA, Bell RJ, et al. The prevalence of sexual dysfunction and sexually-related distress in young women: a cross-sectional survey. Fertil Steril 2020;113:426–34
   PubMed Web of Science ®Google Scholar
• Worsley R, Bell RJ, Gartoulla P, et al. Prevalence and predictors of low sexual desire, sexually related personal distress, and hypoactive sexual desire dysfunction in a community-based sample of midlife women. J Sex Med 2017;14:675–86
   PubMed Web of Science ®Google Scholar
• Zeleke B, Bell RJ, Billah B, Davis SR. Hypoactive sexual desire dysfunction in community-dwelling older women. Menopause 2017;24:391–9
   PubMed Web of Science ®Google Scholar
• Zheng J, Islam MR, Skiba MA, et al. Associations between androgens and sexual function in premenopausal women: a cross-sectional study. Lancet Diabetes Endocrinol 2020;in press
   PubMed Web of Science ®Google Scholar
• Wahlin-Jacobsen S, Pedersen AT, Kristensen E, et al. Is There a correlation between androgens and sexual desire in women? J Sex Med 2015;12:358–73
   PubMed Web of Science ®Google Scholar
• Randolph JF Jr, Zheng H, Avis NE, et al. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab 2015;100:258–66
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970–8
   PubMed Web of Science ®Google Scholar
• Archer JS, Love-Geffen TE, Herbst-Damm KL, et al. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006;13:528–37
   PubMed Web of Science ®Google Scholar
• Bell RJ, Rizvi F, Islam RM, et al. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause 2018;25:704–9
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impotence Res 2013;25:7–11
   PubMed Web of Science ®Google Scholar
• Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. Fertil Steril 2003;79:925–31
   PubMed Web of Science ®Google Scholar
• Davis SR. Intra-vaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. Supplementary data. 2018.pdf. figshare. Dataset. Figshare2018. Available from: https://doi.org/10.26180/5b6517ab522f4
   Google Scholar
• Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: An International Menopause Society White Paper. Climacteric 2018;21:415–27
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Endometrial safety study of transdermal testosterone (300 mcg/d) in naturally postmenopausal women. 2011 Dec 15
   Google Scholar
• Davis SR, Hirschberg AL, Wagner LK, et al. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. J Clin Endocrinol Metab 2009;94:4907–13
   PubMed Web of Science ®Google Scholar
• Hofling M, Lundstrom E, Azavedo E, et al. Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. Climacteric 2007;10:155–63
   PubMed Web of Science ®Google Scholar
• Glaser R, Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas 2015;82:291–5
   PubMed Web of Science ®Google Scholar
• Guerrieri GM, Martinez PE, Klug SP, et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause 2014;21:952–61
   PubMed Web of Science ®Google Scholar
• Fooladi E, Reuter SE, Bell RJ, et al. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause 2015;22:44–9
   PubMed Web of Science ®Google Scholar
• El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric 2007;10:335–43
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in menopausal women not taking estrogen therapy. N Engl J Med 2008;359:2005–17
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121–31
   PubMed Web of Science ®Google Scholar
• Shifren J, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006;13:770–9
   PubMed Web of Science ®Google Scholar
• Braunstein G, Shifren J, Simon J, et al. Testosterone patches for the treatment of low sexual desire in surgically menopausal women. Proceedings of the 14th Annual Meeting of the North American Menopause Society. 2003
   Google Scholar
• Davis SR, van der Mooren MJ, van Lunsen RHW, et al. The efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13:387–96
   PubMed Web of Science ®Google Scholar